KIR2DS1 genotype predicts for complete cytogenetic response and survival in newly diagnosed chronic myeloid leukemia patients treated with imatinib

Leukemia

Volumn 26, Issue 2, 2012, Pages 296-302

  Marin, D ^a   Gabriel, I H ^a   Ahmad, S ^a   Foroni, L ^a   De Lavallade, H ^a   Clark, R ^b   O'Brien, S ^b   Sergeant, R ^a   Hedgley, C ^c   Milojkovic, D ^d   Khorashad, J S ^a   Bua, M ^a   Alsuliman, A ^a   Khoder, A ^a   Stringaris, K ^a   Cooper, N ^a   Davis, J ^d   Goldman, J M ^a   Apperley, J F ^a   Rezvani, K ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

^c NEWCASTLE UNIVERSITY   (United Kingdom)

^d IMPERIAL COLLEGE HEALTHCARE NHS TRUST   (United Kingdom)

Author keywords

chronic myeloid leukemia; imatinib response; killer immunoglobulin like receptors; natural killer cells

Indexed keywords

HLA C ANTIGEN; HYDROXYUREA; IMATINIB; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR; KIR2DL2 PROTEIN; KIR2DL3 PROTEIN; KIR2DL5A PROTEIN; KIR2DL5B PROTEIN; KIR2DS1 PROTEIN; KIR2DS2 PROTEIN; KIR2DS3 PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ALLELE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; COMPLETE CYTOGENETIC RESPONSE; CYTOGENETICS; FEMALE; GENOTYPE; HLA TYPING; HUMAN; IMMUNOGENETICS; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REVIEW; TREATMENT RESPONSE;

EID: 84856704243     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2011.180     Document Type: Review

References (51)

1. Druker BJ, Guilhot F, O'Brien SG, Gathmann I, Kantarjian H, Deininger MW et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006; 355: 2408-2417. (Pubitemid 44903745)
2. Hughes TP, Kaeda J, Branford S, Rudzki Z, Hochhaus A, Hensley ML et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med 2003; 349: 1423-1432. (Pubitemid 37211057)
3. Kolb HJ, Schmid C, Barrett AJ, Schendel DJ. Graft-versus-leukemia reactions in allogeneic chimeras. Blood 2004; 103: 767-776. (Pubitemid 38129531)
4. Caligiuri MA. Human natural killer cells. Blood 2008; 112: 461-469.
5. Lanier LL. NK cell recognition. Annu Rev Immunol 2005; 23: 225-274. (Pubitemid 40563170)
6. Vivier E, Nunes JA, Vely F. Natural killer cell signaling pathways. Science 2004; 306: 1517-1519. (Pubitemid 39564941)
7. Clausen J, Wolf D, Petzer AL, Gunsilius E, Schumacher P, Kircher B et al. Impact of natural killer cell dose and donor killer-cell immunoglobulin-like receptor (KIR) genotype on outcome following human leucocyte antigen-identical haematopoietic stem cell transplantation. Clin Exp Immunol 2007; 148: 520-528. (Pubitemid 46701023)
8. Cooley S, Trachtenberg E, Bergemann TL, Saeteurn K, Klein J, Chap T et al. Donors with group B KIR haplotypes improve relapsefree survival after unrelated hematopoietic cell transplantation for acute myelogenous leukemia. Blood 2009; 113: 726-732.
9. Kroger N, Binder T, Zabelina T, Wolschke C, Schieder H, Renges H et al. Low number of donor activating killer immunoglobulinlike receptors (KIR) genes but not KIR-ligand mismatch prevents relapse and improves disease-free survival in leukemia patients after in vivo T-cell depleted unrelated stem cell transplantation. Transplantation 2006; 82: 1024-1030. (Pubitemid 44632116)
10. Ruggeri L, Capanni M, Urbani E, Perruccio K, Shlomchik WD, Tosti A et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002; 295: 2097-2100. (Pubitemid 34229476)
11. Sconocchia G, Lau M, Provenzano M, Rezvani K, Wongsena W, Fujiwara H et al. The antileukemia effect of HLA-matched NK and NK-T cells in chronic myelogenous leukemia involves NKG2Dtarget-cell interactions. Blood 2005; 106: 3666-3672. (Pubitemid 41609209)
12. Yong AS, Keyvanfar K, Hensel N, Eniafe R, Savani BN, Berg M et al. Primitive quiescent CD34+ cells in chronic myeloid leukemia are targeted by in vitro expanded natural killer cells, which are functionally enhanced by bortezomib. Blood 2009; 113: 875-882.
13. Kreutzman A, Juvonen V, Kairisto V, Ekblom M, Stenke L, Seggewiss R et al. Mono/oligoclonal T and NK cells are common in chronic myeloid leukemia patients at diagnosis and expand during dasatinib therapy. Blood 2010; 116: 772-782.
14. Borg C, Terme M, Taieb J, Menard C, Flament C, Robert C et al. Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell-dependent antitumor effects. J Clin Invest 2004; 114: 379-388. (Pubitemid 39071610)
15. Cebo C, Da RS, Wittnebel S, Turhan AG, Abdelali J, Caillat-Zucman S et al. The decreased susceptibility of Bcr/Abl targets to NK cell-mediated lysis in response to imatinib mesylate involves modulation of NKG2D ligands, GM1 expression, and synapse formation. J Immunol 2006; 176: 864-872. (Pubitemid 43099683)
16. Kantarjian HM, Talpaz M. Definition of the accelerated phase of chronic myelogenous leukemia. J Clin Oncol 1988; 6: 180-182.
17. O'Brien SG, Deininger MW. Imatinib in patients with newly diagnosed chronic-phase chronic myeloid leukemia. Semin Hematol 2003; 40: 26-30.
18. Druker BJ, Guilhot F, O'Brien SG, Gathmann I, Kantarjian H, Deininger MW et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006; 355: 2408-2417. (Pubitemid 44903745)
19. O'Brien SG, Deininger MW. Imatinib in patients with newly diagnosed chronic-phase chronic myeloid leukemia. Semin Hematol 2003; 40: 26-30.
20. National Institutes of Health National Cancer Institute. Cancer Therapy Evaluation Program: Common Toxicity Criteria. National Institutes of Health National Cancer Institute: Bethesda, MD, 1998.
21. Baccarani M, Castagnetti F, Gugliotta G, Palandri F, Soverini S. Response definitions and European Leukemianet Management recommendations. Best Pract Res Clin Haematol 2009; 22: 331-341.
22. Kantarjian HM, Talpaz M. Definition of the accelerated phase of chronic myelogenous leukemia. J Clin Oncol 1988; 6: 180-182.
23. Velickovic M, Velickovic Z, Dunckley H. Diversity of killer cell immunoglobulin-like receptor genes in Pacific Islands populations. Immunogenetics 2006; 58: 523-532. (Pubitemid 44025527)
24. Hsu KC, Chida S, Geraghty DE, Dupont B. The killer cell immunoglobulin-like receptor (KIR) genomic region: gene-order, haplotypes and allelic polymorphism. Immunol Rev 2002; 190: 40-52. (Pubitemid 36071925)
25. Single RM, Martin MP, Meyer D, Gao X, Carrington M. Methods for assessing gene content diversity of KIR with examples from a global set of populations. Immunogenetics 2008; 60: 711-725.
26. Sokal JE, Cox EB, Baccarani M, Tura S, Gomez GA, Robertson JE et al. Prognostic discrimination in "good-risk" chronic granulocytic leukemia. Blood 1984; 63: 789-799. (Pubitemid 14141296)
27. de Lavallade H, Apperley JF, Khorashad JS, Milojkovic D, Reid A, Bua M et al. Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis. J Clin Oncol 2008; 26: 3358-3363.
28. Grzywacz B, Miller JS, Verneris MR. Use of natural killer cells as immunotherapy for leukaemia. Best. Pract Res Clin Haematol 2008; 21: 467-483.
29. Sconocchia G, Lau M, Provenzano M, Rezvani K, Wingsena W, Fujiwara H et al. The antileukemia effect of HLA-matched NK and NK-T cells in chronic myelogenous leukemia involves NKG2Dtarget-cell interactions. Blood 2005; 106: 3666-3672. (Pubitemid 41609209)
30. Clausen J, Wolf D, Petzer AL, Gunsilius E, Schumacher P, Kircher B et al. Impact of natural killer cell dose and donor killer-cell immunoglobulin-like receptor (KIR) genotype on outcome following human leucocyte antigen-identical haematopoietic stem cell transplantation. Clin Exp Immunol 2007; 148: 520-528. (Pubitemid 46701023)
31. Giebel S, Locatelli F, Lamparelli T, Velardi, Davies S, Frumento G et al. Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors. Blood 2003; 102: 814-819. (Pubitemid 36917769)
32. Miller JS, Cooley S, Parham P, Farag SS, Verneris MR, Mc Queen KL et al. Missing KIR ligands are associated with less relapse and increased graft-versus-host disease (GVHD) following unrelated donor allogeneic HCT. Blood 2007; 109: 5058-5061. (Pubitemid 46827806)
33. Ruggeri L, Capanni M, Urbani E, Perruccio, Shlomick WD, Tosti A et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002; 295: 2097-2100. (Pubitemid 34229476)
34. Gabriel IH, Sergeant R, Szydlo R, Apperley JF, DeLavallade H, Alsuliman A et al. Interaction between KIR3DS1 and HLA-Bw4 predicts for progression-free survival following autologous stem cell transplantation in patients with multiple myeloma. Blood 2010; 116: 2033-2039.
35. Hsu KC, Chida S, Geraghty DE, Dupont B. The killer cell immunoglobulin-like receptor (KIR) genomic region: gene-order, haplotypes and allelic polymorphism. Immunol Rev 2002; 190: 40-52. (Pubitemid 36071925)
36. Single RM, Martin MP, Meyer D, Gao X, Carrington M. Methods for assessing gene content diversity of KIR with examples from a global set of populations. Immunogenetics 2008; 60: 711-725.
37. Martin MP, Nelson G, Lee JH, Pellett F, Gao X, Wade J et al. Cutting edge: susceptibility to psoriatic arthritis: influence of activating killer Ig-like receptor genes in the absence of specific HLA-C alleles. J Immunol 2002; 169: 2818-2822. (Pubitemid 35013118)
38. Stewart CA, Laugier-Anfossi F, Vely F, Saulquin X, Riedmuller J, Tisserant A et al. Recognition of peptide-MHC class I complexes by activating killer immunoglobulin-like receptors. Proc Natl Acad Sci USA 2005; 102: 13224-13229. (Pubitemid 41325005)
39. Biassoni R, Pessino A, Malaspina A, Cantoni, Bottino C, Sivori S et al. Role of amino acid position 70 in the binding affinity of p50.1 and p58.1 receptors for HLA-Cw4 molecules. Eur J Immunol 1997; 27: 3095-3099. (Pubitemid 28018001)
40. Arase H, Mocarski ES, Campbell AE, Hill AB, Lanier LL. Direct recognition of cytomegalovirus by activating and inhibitory NK cell receptors. Science 2002; 296: 1323-1326. (Pubitemid 34522789)
41. Daniels KA, Devora G, Lai WC, O'Donnell CL, Bennett M, Welsh RM. Murine cytomegalovirus is regulated by a discrete subset of natural killer cells reactive with monoclonal antibody to Ly49 h. J Exp Med 2001; 194: 29-44. (Pubitemid 32660435)
42. Smith HRC, Heusel JW, Mehta IK, Kim S, Dorner BG, Naidenko OV et al. Recognition of a virus-encoded ligand by a natural killer cell activation receptor. Proc Natl Acad Sci USA 2002; 99: 8826-8831. (Pubitemid 34693643)
43. Vivier E, Biron CA. A pathogen receptor on natural killer cells. Science 2002; 296: 1248-1249. (Pubitemid 34522766)
44. Sconocchia G, Lau M, Provenzano M, Rezvani K, Wonsenga W, Fujiwara H et al. The antileukemia effect of HLA-matched NK and NK-T cells in chronic myelogenous leukemia involves NKG2Dtarget-cell interactions. Blood 2005; 106: 3666-3672. (Pubitemid 41609209)
45. Yong AS, Keyvanfar K, Hensel N, Enaife R, Savani BN, Berg M et al. Primitive quiescent CD34+ cells in chronic myeloid leukemia are targeted by in vitro expanded natural killer cells, which are functionally enhanced by bortezomib. Blood 2009; 113: 875-882.
46. Borg C, Terme M, Taieb J, Menard C, Flament C, Robert C et al. Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell-dependent antitumor effects. J Clin Invest 2004; 114: 379-388. (Pubitemid 39071610)
47. Salih J, Hilpert J, Placke T, Grunebach F, Steinle A, Salih HR et al. The BCR/ABL-inhibitors imatinib, nilotinib and dasatinib differentially affect NK cell reactivity. Int J Cancer 2010; 127: 2119-2128.
48. Mustjoki S, Ekblom M, Arstila TP, Dybedal L, Epling-Burnette PK, Guihot F et al. Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy. Leukemia 2009; 23: 1398-1405.
49. Ghio M, Contini P, Negrini S Mazzei C, Zocchi MR, Poggi A. Soluble HLA-I-mediated secretion of TGF-beta1 by human NK cells and consequent down-regulation of anti-tumor cytolytic activity. Eur J Immunol 2009; 39: 3459-3468.
50. Nakamura K, Kitani A, Strober W. Cell contact-dependent immunosuppression by CD4(+)CD25(+) regulatory T cells is mediated by cell surface-bound transforming growth factor beta. J Exp Med 2001; 194: 629-644. (Pubitemid 32844773)
51. Naka K, Hoshii T, Muraguchi T, Tadokoro, Ooshio T, Kondo Y et al. TGF-beta-FOXO signalling maintains leukaemia-initiating cells in chronic myeloid leukaemia. Nature 2010; 463: 676-680.